论文部分内容阅读
氨哮素(Clenbuterol)又称盐酸双氯醇胺、氨双氯喘通,国外研究代号NAB_(365),是一种新型强效选择性β_2受体兴奋剂。上海第17制药厂试制成功之后,经过30余个医疗单位使用其片剂、含片、气雾剂,观察病员达2,000余例,认为平喘效果极为明显,已于1977年鉴定。上海医药工业研究院、华东医院等单位为了提高氨哮素的平喘效果,从剂型方面着手研究,试制了氨哮素栓剂,由20个医疗单位共同协作,观察了524例病员,一致认为氨哮素栓剂的平喘效果较好,持续时间较长。
Clenbuterol, also known as dichlorohydrine hydrochloride, ammonia dichloride asthma, foreign research code NAB_ (365), is a new potent and selective β_2 receptor agonist. After the successful trial of the 17th Shanghai Pharmaceutical Factory, more than 2,000 patients were observed using tablets, troches and aerosols after more than 30 medical units were admitted to the trial. The anti-asthmatic effect was extremely evident and was appraised in 1977. Shanghai Institute of Pharmaceutical Industry, East China Hospital and other units in order to improve the asthma Asthma anti-asthma effect, starting from the dosage form of research, trial production of ammonia suppository suppository, 20 medical units work together to observe the 524 patients, agreed that ammonia Asthma suppository asthma relief effect is better, longer duration.